Analyzing Innocoll Holdings PLC (INNL) & The Competition
Innocoll Holdings PLC (NASDAQ: INNL) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Innocoll Holdings PLC to similar businesses based on the strength of its profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.
Earnings and Valuation
This table compares Innocoll Holdings PLC and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Innocoll Holdings PLC||N/A||N/A||-1.41|
|Innocoll Holdings PLC Competitors||$8.20 billion||$2.68 billion||-1.11|
Innocoll Holdings PLC’s competitors have higher revenue and earnings than Innocoll Holdings PLC. Innocoll Holdings PLC is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
34.2% of Innocoll Holdings PLC shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.9% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Innocoll Holdings PLC has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Comparatively, Innocoll Holdings PLC’s competitors have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.
This table compares Innocoll Holdings PLC and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Innocoll Holdings PLC||-1,051.20%||N/A||-138.53%|
|Innocoll Holdings PLC Competitors||-2,882.31%||-68.19%||-9.01%|
This is a breakdown of recent recommendations and price targets for Innocoll Holdings PLC and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Innocoll Holdings PLC||0||3||1||0||2.25|
|Innocoll Holdings PLC Competitors||831||3724||6752||183||2.55|
Innocoll Holdings PLC presently has a consensus price target of $4.50, indicating a potential upside of 91.49%. As a group, “Pharmaceuticals” companies have a potential upside of 26.89%. Given Innocoll Holdings PLC’s higher possible upside, research analysts plainly believe Innocoll Holdings PLC is more favorable than its competitors.
Innocoll Holdings PLC competitors beat Innocoll Holdings PLC on 8 of the 11 factors compared.
Innocoll Holdings PLC Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with MarketBeat.com's FREE daily email newsletter.